不安定なアンギナ・プクトリス. 進行性アンギナと中間冠動脈症候群における血小板の行動と予後
P Grande1, A M Grauholt, J K Madsen
1Medical Department B (Cardiology), Rigshospitalet, University Hospital, Copenhagen, Denmark.
Circulation
|January 1, 1990
まとめ
中級冠動脈症候群の患者は,高結集血小板と高血栓素B2を示しており,血小板の行動が変化していることを示しています. これは進行性アンギナ患者とは対照的であり,不安定なアンギナの病理生理学的メカニズムが異なっていることを示唆しています.
科学分野:
- 心臓病学 心臓病学
- 血液学 ヘマトロジ
- トロンボシス (Thrombosis) とは
背景:
- 不安定性アンギナには,中間冠動脈症候群 (休息痛,STうつ) や進行性アンギナなどの症状が含まれます.
- 血小板活性化は,急性冠動脈症候群の病理生理学において重要な役割を果たします.
- 不安定性アンギナの異なるサブセットにおける血小板の特徴的な行動を理解することは,予後と治療に不可欠です.
研究 の 目的:
- 中級冠動脈症候群の患者の血小板の集積と活性化マーカーを,進行性心房痛と比較する.
- 健康な対照群との関係で血小板の行動を評価する.
主な方法:
- アラキドン酸を用いたex vivo血小板集積測定法.
- 血清トロンボキサンB2,血ベータトロンボグロブリン,および血小板因子の測定 4.
- 13人の中級冠動脈症候群患者,14人の進行性アンギナ患者,および20人の健康な対照群の比較.
主要な成果:
- 両方の不安定性アンギナ群は,対照群と比較して,血小板の過剰集積を示した (p <0.01).
- インターメディエイト冠動脈症候群の患者は,血清トロンボキサンB2,血ベータトロンボグロブリン,および血小板因子4 (p <0.01) の有意な増加を示した.
- 進行性 angina の患者は,コントロールと比較して,これらのマーカーの有意に異なるレベルを示さなかった.
結論:
- 中級冠動脈症候群の患者は,血小板の行動がひどく変化し,過集積と活性化マーカーの増加が特徴です.
- 中級冠動脈症候群におけるこれらの血小板の変化は,進行性心房痛において観察されるものとは異なる.
- 中級冠動脈症候群における血小板の行動の変化は,冠動脈血栓のより高い頻度と,より悪い予後と相関することがあります.
関連する概念動画
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:30Angina I: Introduction
Definition and Symptoms: Angina (angina pectoris) is chest pain or discomfort caused by myocardial ischemia, which occurs when the heart muscle receives insufficient oxygen-rich blood. It typically manifests as pressing, squeezing, or crushing sensations in the chest and may radiate to the shoulders, arms, neck, jaw, or back.Primary Cause: In a healthy state, the coronary arteries can dilate (widen) to increase blood flow and meet the increased oxygen demand during physical activity or...
01:27Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
01:29Angina III: Clinical Manifestations and Assessment
Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...